The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Novel drug development is onerous, time consuming and overpriced process with particularly low success and relatively high enfeebling rates. To overcome this burden, drug repositioning approach is being used to predict the possible therapeutic effects of FDA approved drugs in different diseases. Herein, we designed a computational and enzyme inhibitory mechanistic approach to fetch the promising drugs from the pool of FDA approved drugs against AD. The binding interaction patterns and conformations of screened drugs within active region of AChE were confirmed through molecular docking profiles. The possible associations of selected drugs with AD genes were predicted by pharmacogenomics analysis and confirmed through data mining. The stability behaviour of docked complexes (Drugs-AChE) were checked by MD simulations. The possible therapeutic potential of repositioned drugs against AChE were checked by in vitro analysis. Taken together, Cinitapride displayed a comparable results with standard and can be used as possible therapeutic agent in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
(2009) · doi:10.1007/978-3-540-29678-2 · Cited by 900
Comparative evaluation of 11 scoring functions for molecular docking.
Wang, R., Lu, Y., & Wang, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0203783 · Cited by 849
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
GSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., & Polleux, F. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.003 · Cited by 351
Geekiyanage, H., & Chan, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3883-11.2011 · Cited by 254
On the Integration of In Silico Drug Design Methods for Drug Repurposing
March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00298 · Cited by 235
Licastro, F., Grimaldi, L. M. E., Bonafè, M., Martina, C., Olivieri, F., Cavallone, L., Giovanietti, S., Masliah, E., & Franceschi, C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00013-7 · Cited by 182
Cited by
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review
Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., Fernández-Brillet, L., Fernández-Martínez, J. L., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094645 · Cited by 317
“Drug repurposing, also called drug repositioning, of the already known FDA approved compounds for new therapeutic uses is a very effective methodology to find a cure in rare diseases where the economic constraints for new drug development are very important [75].”
BackgroundSelf-citationPillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113098 · Cited by 35
“Darifenacin was previously found as one of the best ten candidates for drug repurposing using docking methods [80].”
Background
Metadata
- Authors
- Hassan, M., Raza, H., Abbasi, M. A., Moustafa, A. A., & Seo, S.-Y.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 109
- Pages
- 2513-2526
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W2902167104
- Cited by
- 61
- References
- 24
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. https://app.cochat.ai/papers/10.1016/j.biopha.2018.11.115
- The paper
- Hassan, M., Raza, H., Abbasi, M. A., Moustafa, A. A., & Seo, S.-Y. (2019). The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2018.11.115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.